Conditions that affect the brain, in particular neurodegenerative disorders such as Alzheimer’s, are some of the most challenging conundrums in the field of medicine to unravel. There is presently no treatment or cure available for Alzheimer’s disease, which affects millions of individuals all over the world. However, patients who took lecanamab throughout the 18-month experiment experienced a reduction in amyloid beta plaque in their brains that was statistically significant in comparison to those who took a placebo, and it reduced cognitive deterioration by 27 percent. That’s genuinely fascinating! After the acquired results of the phase 3 trial showed that lecanemab reduces cognitive loss in early-stage Alzheimer’s patients, the drug was granted clearance by the FDA in January.
It is noteworthy that lecanemab causes less ARIA (10 percent) than other anti-Aβ antibodies such as aducanumab (35 percent), gantenerumab (30 percent), or donanemab (27 percent), explain the researchers.
An antibody known as 3E8 has been produced by the research team. This antibody targets a protein that is found in circulating plasma to achieve the same result. They feel that their findings indicate that 3E8 has the potential to treat Alzheimer’s disease, either on its own or in conjunction with other drugs, such as lecanemab, with perhaps more widespread effects. Alzheimer’s disease is characterized by the accumulation of tangles and plaques made of two main types of proteins: tau and amyloid beta (A). Such a thing results in the loss of brain cells and a reduction in the volume of the brain. When the contact system is activated, an excessive amount of peptide known as bradykinin is produced. This peptide has the ability to widen blood vessels, which might result in the ARIA adverse reactions that are more frequent with other anti-A treatments. Lecanemab appears to function by reducing the buildup of A and stopping protofibrils by stimulating the contact system, which leads to a decrease in the synthesis of bradykinin.
More research and data will be soon available.
